These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 7997385)

  • 1. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group.
    Patterson JH; Adams KF; Applefeld MM; Corder CN; Masse BR
    Pharmacotherapy; 1994; 14(5):514-21. PubMed ID: 7997385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response study of intravenous torsemide in congestive heart failure.
    Hariman RJ; Bremner S; Louie EK; Rogers WJ; Kostis JB; Nocero MA; Jones JP
    Am Heart J; 1994 Aug; 128(2):352-7. PubMed ID: 8037103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six-week study of torsemide in patients with congestive heart failure.
    Goebel KM
    Clin Ther; 1993; 15(6):1051-9. PubMed ID: 8111802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-response study of orally administered torsemide in patients with ascites due to cirrhosis.
    Applefeld JJ; Kasmer RJ; Hak LJ; Dukes GE; Wermeling DP; McClain CJ
    Aliment Pharmacol Ther; 1994 Aug; 8(4):397-402. PubMed ID: 7986964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacodynamics of torsemide in patients with congestive heart failure.
    Vargo D; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC
    Clin Pharmacol Ther; 1994 Jul; 56(1):48-54. PubMed ID: 8033494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease.
    Vasavada N; Saha C; Agarwal R
    Kidney Int; 2003 Aug; 64(2):632-40. PubMed ID: 12846760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.
    Vargo DL; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC
    Clin Pharmacol Ther; 1995 Jun; 57(6):601-9. PubMed ID: 7781259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of oral administration of furosemide and torsemide in healthy dogs.
    Hori Y; Takusagawa F; Ikadai H; Uechi M; Hoshi F; Higuchi S
    Am J Vet Res; 2007 Oct; 68(10):1058-63. PubMed ID: 17916010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure.
    Noe LL; Vreeland MG; Pezzella SM; Trotter JP
    Clin Ther; 1999 May; 21(5):854-66. PubMed ID: 10397380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal excretory responses to single and repeated administration of diuretics in healthy subjects: clinical connotations.
    Reyes AJ; Leary WP
    Cardiovasc Drugs Ther; 1993 Jan; 7 Suppl 1():29-44. PubMed ID: 8435375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Torsemide as a Primary Choice in Edema Associated with Heart Failure.
    Ezhilan J; Dighe S; Shah C; Tiwaskar M; Chopra V; Patil R; Srivastava P; Mahilmaran A; Pradhan A; Rahman S; Malviya A; Gupta A; Teja P; Francis F; Sugumaran A
    J Assoc Physicians India; 2024 Sep; 72(9S):19-23. PubMed ID: 39291568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
    Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
    Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study.
    Scheen AJ; Vancrombreucq JC; Delarge J; Luyckx AS
    Eur J Clin Pharmacol; 1986; 31 Suppl():35-42. PubMed ID: 3780838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure.
    Kramer WG; Smith WB; Ferguson J; Serpas T; Grant AG; Black PK; Brater DC
    J Clin Pharmacol; 1996 Mar; 36(3):265-70. PubMed ID: 8690821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic properties of orally administered torsemide in healthy horses.
    Agne GF; Jung SW; Wooldridge AA; Duran SH; Ravis W; Toribio R
    J Vet Intern Med; 2018 Jul; 32(4):1428-1435. PubMed ID: 29770976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Torsemide: a new loop diuretic.
    Fowler SF; Murray KM
    Am J Health Syst Pharm; 1995 Aug; 52(16):1771-80; quiz 1814-5. PubMed ID: 8528833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Torsemide: a pyridine-sulfonylurea loop diuretic.
    Blose JS; Adams KF; Patterson JH
    Ann Pharmacother; 1995 Apr; 29(4):396-402. PubMed ID: 7633019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the tolerance and diuretic properties of torasemide following oral or intravenous administration to healthy volunteers.
    Lambe R; Kennedy O; Kenny M; Darragh A
    Eur J Clin Pharmacol; 1986; 31 Suppl():9-14. PubMed ID: 3780841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saluretic effect of the loop diuretic torasemide in chronic renal failure. Interdependence of electrolyte excretion.
    Knauf H; Mutschler E
    Eur J Clin Pharmacol; 1990; 39(4):337-43. PubMed ID: 2076714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The influence of ACE inhibitors on urinary electrolyte secretion and the response to transitory hypovolemia in chronic heart failure].
    Marenzi G; Lauri G; Assanelli E; Grazi M; Guazzi M; Berna G; Salvioni A; Agostoni P
    Cardiologia; 1997 Dec; 42(12):1277-83. PubMed ID: 9534323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.